NCLA Partnership in Disruptive Technologies Innovation Fund (DTIF)- BioVAS

Feb 02 2024 Posted: 16:40 GMT

The NCLA are delighted to be a part of BioVAS: Biological Micro-Surgical Vessel Advanced Closure System project, funded by the Disruptive Technologies Innovation Fund (DTIF) Call 4 on Chronic Venous Disease treatment, in partnership with InVera Medical, MET Technology Gateway – Atlantic Technological University, and ICS Medical Devices. 

This pioneering €4.6 million consortium project will focus on the development of BioVAS - a microvascular vessel wall intervention specifically designed for the treatment of venous leg ulceration. At its core the BioVAS project exemplifies industrial research, aiming to acquire new knowledge and skills that will significantly enhance the treatment of vascular disease.

.

The Disruptive Technologies Innovation Fund is a €500 million fund established under the National Development Plan (NDP) in 2018 by the Department of Enterprise, Trade and Employment with administrate support from Enterprise Ireland.

PreviousNext